glp-1 in type 2 diabetes receptor agonists the treatment of – state-of-the-art How GLP-1 Medicines Help Manage

[DOI] [PMC free article] [PubMed] [Google Scholar] 47.Salinas C.B.G., Lu T.T., Gabery S., Marstal K., Alanentalo T., Mercer A.J., Cornea A., Conradsen K., Hecksher-Sorensen J., Dahl A.B., et al

However, some of the evidence is unclear, and further research into the topic is necessary

Limitations include relatively short treatment periods (6 weeks per arm), potential carryover effects despite washout, modest sample size limiting power for subgroup analyses and exclusion of newer agents (e.g., tapentadol) and long-term safety outcomes, which may restrict applicability to broader clinical practice

Its not your imagination and its not a sign that the medication is too strong. Its simply your body recalibrating